In addition, the Times found out that FDA authorities did not enable company researchers to send 2 abstracts for research studies on Shingrix, a shingles vaccine, to a significant drug security conference. The research studies supposedly strengthened recognized effectiveness and security information of the vaccines.

HHS representative Andrew Nixon stated in a declaration that the axed COVID research studies “were withdrawn since the authors drew broad conclusions that were not supported by the underlying information. The FDA acted to secure the stability of its clinical procedure and make sure that any work connected with the company satisfies its high requirements.”

Of the shingles research study taking a look at effectiveness, he stated, “The style of that research study fell outside the firm’s province.” Nixon did not deal with why the Shingrix security research study was kept.